-- Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance –

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced an upcoming presentation highlighting WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product. The data support the potential of WU-NK-101 to overcome resistance to immune checkpoint blockade (ICB) therapy and will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14 – 19, 2023 in Orlando, Florida.

The details of Wugen’s presentation at AACR are as follows:

Title: WU-NK-101 as Salvage Therapy Post Immune Checkpoint Blockade (ICB)

Session: Immunotherapy Strategies and Mechanisms

Session Date and Time: Wednesday, April 19, 2023, 9:00 a.m. - 12:30 p.m. ET

Location: Section 25

Poster Number: 5

Abstract Number: 6418

Presenter: Tom Leedom

Additional meeting information can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2023/.

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary Moneta™ platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta™ platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005318/en/